Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ian M. Mawer is active.

Publication


Featured researches published by Ian M. Mawer.


Tetrahedron | 1989

The total synthesis of myo-inositol polyphosphates

Joseph P. Vacca; S. Jane deSolms; Joel R. Huff; David C. Billington; Raymond Baker; Janusz Jozef Kulagowski; Ian M. Mawer

Abstract Total synthesis of the individual enantiomers of myo-inositol 4-phosphate ( 15 ), myo-inositol 1,4-bisphosphate ( 2 ) and myo-inositol 1,4,5-trisphosphate ( 1 ), together with syntheses of racemic myo-inositol 1,3,4-trisphosphate ( 4 ) and myo-inositol 2,4,5-trisphosphate ( 5 ) are reported. The syntheses feature the use of camphanic acid esters for resolution of protected inositols, and the use of tetrabenzylpyrophosphate as an efficient phosphorylating agent for polyhydroxy alcohols.


Neuropharmacology | 1998

Discriminative stimulus properties of the putative dopamine D3 receptor agonist, (+)-PD 128907: role of presynaptic dopamine D2 autoreceptors.

Linda J. Bristow; Gina P Cook; Smita Patel; Neil Roy Curtis; Ian M. Mawer; Janusz Jozef Kulagowski

The putative D3 receptor agonist, (+)-PD 128907, is widely used to study the functional relevance of D3 receptors in vivo. Given that non-selective D2/3/4 receptor agonists serve as effective discriminative stimuli in rats we have trained animals to discriminate (+)-PD 128907 (30 microg kg(-1), s.c.) from saline and examined the pharmacological specificity of the response. Consistent with a D3 receptor mediated response, the non-selective D2/3 receptor agonist apomorphine and the D3 preferring agonists 7-OH-DPAT and (-) quinpirole generalised to the cue whilst the D2/3 receptor antagonists haloperidol, raclopride, spiperone and (+)-butaclamol antagonised drug lever responding. In contrast, the D1 selective agonist (+/-)-SKF 81297 and D1/5 selective antagonist, R-(+)-SCH 23390 had no effect. Results also suggest that presynaptic dopamine receptors are involved. Thus the dopamine depleting agent alpha-methyl-p-tyrosine potentiated the effects of a submaximal dose of (+)-PD 128907 whereas amphetamine failed to generalise per se and blocked (+)-PD 128907 lever selection. However, studies using subtype selective antagonists argue against a role for the D3 receptor. Thus the 10-fold selective D2 receptor antagonist L-741,626 blocked the (+)-PD 128907 discriminative stimulus whereas L-745,829 and GR 103,691, antagonists > 40 and > 100-fold selective for D3 receptors, failed to modify the response. These results suggest that presynaptic D2 receptors mediate the discriminative stimulus properties of (+)-PD 128907 and highlight the lack of selectivity of (+)-PD 128907 for D3 receptors in vivo.


Bioorganic & Medicinal Chemistry Letters | 1993

Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists

Paul D. Leeson; Raymond Baker; Robert W. Carling; Janusz Jozef Kulagowski; Ian M. Mawer; Mark Peter Ridgill; Michael Rowley; Julian D. Smith; Ian Stansfield; Graeme Irvine Stevenson; Alan C. Foster; John A. Kemp

Abstract 3-Substituted-2-quinoloners ( 6–8 ) have been identified as glycine-site N-methyl-D-aspartate receptor antagonists. It is proposed that the α-phenyl lactam unit in the potent 4-hydroxy-3-phenyl derivatives ( 7d and 8b , L-701,315) may act as a glycine bioisostere in receptor recognition.


Journal of The Chemical Society-perkin Transactions 1 | 1989

The total synthesis of myo-inositol phosphates via myo-inositol orthoformate

David C. Billington; Raymond Baker; Janusz Jozef Kulagowski; Ian M. Mawer; Joseph P. Vacca; S. Jane deSolms; Joel R. Huff

Novel selective alkylations of myo-inositol orthoformate (4) have been used to prepare a series of protected myo-inositol derivatives, (5a–e), (7), (10), (12), and (16). These intermediates have been used in efficient total syntheses of myo-inositol 2-phosphate, (9); myo-inositol 4-phosphate, (6); myo-inositol 1,3-bisphosphate, (18); and myo-inositol 1,3,4,5-tetrakisphosphate (14). This report represents the first total synthesis of the important natural metabolites (14) and (18) and significantly improved methods of preparation of (6) and (9).


Bioorganic & Medicinal Chemistry Letters | 1995

Tetramic acids as novel glycine site antagonists

Ian M. Mawer; Janusz Jozef Kulagowski; Paul D. Leeson; Sarah Grimwood; George Marshall

Abstract Tetramic acids ( 9 ) have been designed as novel glycine site N-methyl-D-aspartate receptor antagonists.


Journal of The Chemical Society, Chemical Communications | 1987

Synthesis of myo-inositol 1-phosphate and 4-phosphate, and of their individual enantiomers

David C. Billington; Raymond Baker; Janusz Jozef Kulagowski; Ian M. Mawer

New methodology is described which allows the synthesis of myo-inositol 1-phosphate completely free of contamination by the 2-isomer, and novel resolution procedures have been developed for the preparation of the enantiomers of myo-inositol 1- and 4-phosphates.


Bioorganic & Medicinal Chemistry Letters | 1996

Synthesis and SAR of diiodotyrosine-derived glycine-site N-methyl-D-aspartate receptor ligands

Neil Roy Curtis; Janusz Jozef Kulagowski; Paul D. Leeson; Ian M. Mawer; Mark Peter Ridgill; Michael Rowley; Sarah Grimwood; George Marshall

Abstract A series of analogues of the novel diiodotyrosine derived NMDA glycine-site ligand (R)-4 was prepared in which the aryl substitution, chain length and amino acid groups were varied. The key structural features for binding are the α-amino acid function, having the (R) absolute stereochemistry, the 3,5-diiodo substituted aromatic ring and a lipophilic group attached at the phenolic oxygen of the tyrosine moiety.


Journal of Medicinal Chemistry | 1996

3-[[4-(4-Chlorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine: An Antagonist with High Affinity and Selectivity for the Human Dopamine D4 Receptor

Janusz Jozef Kulagowski; Howard B. Broughton; Neil Roy Curtis; Ian M. Mawer; Mark Peter Ridgill; Baker R; Frances Emms; Stephen B. Freedman; Rosemarie Marwood; Shil Patel; Ragan Ci; Paul D. Leeson


Journal of Medicinal Chemistry | 1993

3-Nitro-3,4-dihydro-2(1H)-quinolones: Excitatory amino acid antagonists acting at glycine-site NMDA and (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors

Robert W. Carling; Paul D. Leeson; Kevin William Moore; Julian D. Smith; Christopher Richard Moyes; Ian M. Mawer; Steven Thomas; Tony Chan; Raymond Baker; Alan C. Foster; Sarah Grimwood; John A. Kemp; George R. Marshall; Mark D. Tricklebank; Kay L. Saywell


Archive | 1993

Tetramic acid derivatives

Janusz Jozef Kulagowski; Paul D. Leeson; Ian M. Mawer

Collaboration


Dive into the Ian M. Mawer's collaboration.

Researchain Logo
Decentralizing Knowledge